Activation of LXRα regulates cellular cholesterol homeostasis and inhibits infection of PRRSV
This study demonstrates that activating the liver X receptor α (LXRα) with GW3965 inhibits Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infection by remodeling cellular cholesterol homeostasis to deprive the virus of essential lipids and by suppressing virus-induced inflammatory responses.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Viruses are not just biological invaders; they are also opportunistic thieves that rely on the host's own resources to survive. To enter a cell, replicate, and spread, many viruses need specific building blocks found in the cell's membrane, particularly cholesterol. This waxy substance helps maintain the structure of the cell's outer layer and forms specialized platforms where viruses can assemble. When a virus hijacks a cell, it often manipulates the cell's internal chemistry to gather more of these lipids, creating a rich environment that fuels its own reproduction. This relationship between viral infection and the body's management of fats is a critical area of study, especially for diseases that affect livestock and threaten global food security. One such disease is Porcine Reproductive and Respiratory Syndrome, caused by a virus that targets the lungs of pigs. The cells in the pig's lungs that normally fight off infection are the very ones the virus attacks, and understanding how the virus manipulates the cholesterol within these cells could reveal new ways to stop it.
Researchers at Nanjing Agricultural University and the Shandong Academy of Agricultural Sciences have investigated how a specific molecule in the body, known as LXR-alpha, can be used to disrupt this viral strategy. LXR-alpha acts as a master regulator for how cells handle cholesterol. In a healthy state, it ensures that cells do not accumulate too much fat by telling them to release excess cholesterol and stop taking in more. The scientists tested a synthetic drug called GW3965, which activates this regulator, to see if it could protect pig lung cells from the virus. Their work demonstrates that turning on this cellular switch effectively starves the virus of the cholesterol it needs to thrive, while also calming the dangerous inflammation that often accompanies the infection.
The study began by confirming what the virus does to a pig's lungs. When the researchers infected piglets with the virus, they observed a significant buildup of fat and cholesterol in the lung tissue, specifically around the cells that the virus targets. In laboratory tests, they found that when they added extra cholesterol to the cells before introducing the virus, the infection became stronger. This confirmed that the virus actively encourages the host to gather more cholesterol to support its own growth. The virus appears to exploit a specific pathway, using a receptor on the cell surface called LDLR to pull in low-density lipoprotein, a carrier of cholesterol, from the surrounding environment. By increasing the number of these receptors, the virus ensures a steady supply of fuel for its replication.
To counter this, the researchers treated the cells with GW3965. This drug activates LXR-alpha, which then sends two distinct signals to the cell. First, it triggers the breakdown of the LDLR receptors, effectively closing the door on new cholesterol entering the cell. Second, it boosts the production of a transporter protein called ABCA1, which acts like a pump to push existing cholesterol out of the cell and into the surrounding fluid. The result was a cell with significantly lower levels of internal cholesterol. When the virus tried to infect these treated cells, it struggled. The researchers found that the drug did not stop the virus from initially attaching to the cell surface, but it severely hindered the virus's ability to enter the cell and begin replicating. Without the necessary lipid-rich environment, the virus could not build the copies of itself needed to spread.
The study also looked at the broader impact of this treatment on the immune response. Viral infections often trigger a massive release of inflammatory signals, which can damage lung tissue and worsen the disease. The researchers measured the levels of several inflammatory proteins in the cells and found that the GW3965 treatment significantly reduced their production. This suggests that by activating LXR-alpha, the drug not only starves the virus but also helps the body manage the inflammatory storm that the infection causes. The treatment worked by reducing the activity of a specific protein complex known as NLRP3, which is a key driver of this inflammation.
Through a series of experiments involving both live piglets and cells in a dish, the team established a clear chain of events. The virus increases cholesterol uptake to fuel its replication. The drug GW3965 activates a natural cellular regulator that reverses this process, lowering cholesterol levels and blocking the virus's entry and reproduction. The findings suggest that targeting the body's own cholesterol management system offers a promising path to fighting this virus. While the study does not claim to have a cure, it provides a strong theoretical foundation for developing new antiviral strategies that work by remodeling the cellular environment rather than attacking the virus directly. The work highlights how understanding the basic mechanics of cell biology can lead to innovative ways to protect animals from devastating diseases.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.